- |||||||||| Journal: First Confirmed Description of Acremonium egyptiacum from Greece and Molecular Identification of Acremonium and Acremonium-like Clinical Isolates. (Pubmed Central) - Sep 27, 2024
Amphotericin B, itraconazole, posaconazole, voriconazole, terbinafine, amorolfine, and griseofulvin MICs were overall high (GM 12.79-29.49 ?g/mL)...Antifungal susceptibility of the three different A. egyptiacum genotypes was homogeneous. Overall, the high MICs recorded for all systemically administered drugs, and for some topical antifungals against the tested A. egyptiacum and other acremonium-like clinical isolates, justify the routine susceptibility testing of clinical isolates.
- |||||||||| Astat (lanoconazole) / Maruho
PK/PD data, Journal: Pharmacokinetics of lanoconazole in human skin after repeated topical application. (Pubmed Central) - Nov 4, 2022
The obtained data were used to evaluate lanoconazole pharmacokinetics in the stratum corneum. The amount of lanoconazole in the stratum corneum after once daily repeated administration reached a steady state on day 3, and it was eliminated from the stratum corneum with a half-life of approximately 11 h after discontinuing application.
- |||||||||| Clinical, Preclinical, Journal: In Vitro Activity of 23 Antifungal Drugs against 54 Clinical and Environmental Aspergillus oryzae isolates. (Pubmed Central) - Oct 12, 2022
In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy.
- |||||||||| Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
Journal: Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani, and Fusarium incarnatum-equiseti species complexes from onychomycosis in North of Iran. (Pubmed Central) - Oct 12, 2022
Moreover, the minimum inhibitory concentration (MIC) of luliconazole and lanoconazole was in the range of 0.001-1 μg/mL, with the geometric mean of MICs obtained at 0.0103 and 0.0343 μg/mL against Fusarium species, respectively. These findings can increase researchers' knowledge regarding diversity of species, distribution of onychomycosis, and the choice of a proper treatment.
- |||||||||| Journal: Fusarium Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features. (Pubmed Central) - May 30, 2022
The MICs of natamycin, voriconazole, chlorhexidine, lanoconazole, and luliconazole were higher for the FSSC than the non-FSSC, but no significant differences were noted in clinical outcomes, including corneal perforation and final visual acuity. In Taiwan, the FSSC was the most common complex in Fusarium keratitis; its MICs for five tested antifungal agents were higher than those of non-FSSC, but the clinical outcomes did not differ significantly.
- |||||||||| Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: Contact dermatitis caused by efinaconazole and luliconazole. (Pubmed Central) - Jan 18, 2022
However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.
- |||||||||| Jublia (efinaconazole) / Kaken, Bausch Health, Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
Journal: In Vitro Activities of 15 Antifungal Drugs against a Large Collection of Clinical Isolates of Microsporum canis. (Pubmed Central) - Feb 25, 2020
FDA-approved antifungal drugs, that is luliconazole, efinaconazole and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M canis. However, their therapeutic effectiveness remains to be determined in clinical settings.
- |||||||||| fluconazole / Generic mfg., Spherazole (itraconazole) / RA Chem, JW Pharma, Spherics
Journal: High prevalence of itraconazole resistance among Candida parapsilosis isolated from Iran. (Pubmed Central) - Dec 22, 2019
For the purpose of the study, the isolates were subjected to antifungal susceptibility testing against fluconazole (FLZ), itraconazole (ITZ), voriconazole (VRZ), and two new azole drugs, namely luliconazole (LUZU) and lanoconazole (LZN)...This may have been associated with the long-term ITZ prophylaxis/therapy in patients infected with candidiasis. Hence, the adoption of an appropriate antifungal agent is a crucial step for starting the treatment.
- |||||||||| lanoconazole (M1100) / Maruho, Luzu / Bausch Health
Journal: Potent Activity of Luliconazole, Lanoconazole and Eight Comparators against Molecularly Characterizedspecies. (Pubmed Central) - Jun 22, 2019
Luliconazole and lanoconazole demonstrated very low GM MIC values of 0.005 μg/ml and 0.013 μg/ml, respectively, in comparison with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due tospecies.
- |||||||||| Jublia (efinaconazole) / Kaken, Bausch Health
Preclinical, Journal: In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators Against Dermatophyte Isolates. (Pubmed Central) - Jun 22, 2019
The geometric mean MICs were the lowest for luliconazole (0.0005 μg/mL), followed by lanoconazole (0.002 μg/mL), efinaconazole (0.007 μg/mL), terbinafine (0.011 μg/mL), itraconazole (0.095 μg/mL) and fluconazole (12.77 μg/mL). It appears that efinaconazole, lanoconazole and luliconazole are promising candidates for the treatment of dermatophytosis due toand.
|
